Nano Holdings.Inc.

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticle technology in Japan. Its pipeline includes RUNX1 (mRNA) for knee osteoarthritis pain reduction, NC-6100 PRDM14 (siRNA) in Phase I trials for breast cancer, and TUG1 (ASO) for glioblastoma multiforme. The company also offers cosmetic raw materials. Formerly known as NANO MRNA Co., Ltd., it changed its name to Nano Holdings, Inc. in December 2025, was incorporated in 1996, and is headquartered in Minato, Japan.